| Amber Rose Ocampo, OTD, OTR/L | |
|
5355 E High St Unit 113, Phoenix, AZ 85054-5481 | |
| (602) 648-5444 | |
| (602) 772-3801 |
| Full Name | Amber Rose Ocampo |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 5355 E High St Unit 113, Phoenix, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093576118 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OTH-009507 (Arizona) | Primary |
| Provider Name | Orthopedic Specialists Of North America Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1770812828 PECOS PAC ID: 7719014505 Enrollment ID: O20100428000061 |
News Archive
Good news for the millions of people who suffer from skin wounds that won't heal. A team of researchers at The Ohio State University has brought a potentially transformative solution to the problem by creating a portable adhesive patch that drives a continuous, small electrical current to stimulate healing and reduce the risk of infection.
RegeneRx Biopharmaceuticals, Inc. has announced that researchers have found that Thymosin beta 4 (Tβ4), in a dose dependent manner, stimulates oligodendrogenesis, the process by which central nervous system progenitor cells become oligodendrocytes that secrete myelin, the covering of nerve fibers.
Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.
Endo Pharmaceuticals today announced the successful completion of the tender offer by its indirect wholly owned subsidiary, West Acquisition Corp., for all of the outstanding shares of common stock of Penwest Pharmaceuticals Co.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amber Rose Ocampo, OTD, OTR/L Po Box 80217, Phoenix, AZ 85060-0217 Ph: (602) 385-2115 | Amber Rose Ocampo, OTD, OTR/L 5355 E High St Unit 113, Phoenix, AZ 85054-5481 Ph: (602) 648-5444 |
News Archive
Good news for the millions of people who suffer from skin wounds that won't heal. A team of researchers at The Ohio State University has brought a potentially transformative solution to the problem by creating a portable adhesive patch that drives a continuous, small electrical current to stimulate healing and reduce the risk of infection.
RegeneRx Biopharmaceuticals, Inc. has announced that researchers have found that Thymosin beta 4 (Tβ4), in a dose dependent manner, stimulates oligodendrogenesis, the process by which central nervous system progenitor cells become oligodendrocytes that secrete myelin, the covering of nerve fibers.
Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.
Endo Pharmaceuticals today announced the successful completion of the tender offer by its indirect wholly owned subsidiary, West Acquisition Corp., for all of the outstanding shares of common stock of Penwest Pharmaceuticals Co.
› Verified 2 days ago
Rebecca Ebbert, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 7540 N 19th Ave, Phoenix, AZ 85021 Phone: 888-873-4221 Fax: 888-543-2289 | |
Kristina Nalder, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5314 N 7th St, Phoenix, AZ 85014 Phone: 602-277-5006 | |
Tabitha Macziewski, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4600 E Shea Blvd, Suite 101, Phoenix, AZ 85028 Phone: 602-368-8601 Fax: 602-368-8605 | |
Christina Hyland, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4641 N 12th St Ste 100, Phoenix, AZ 85014 Phone: 602-281-2896 | |
Kristel Ferrer, OTD, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5025 E Washington St Ste 108, Phoenix, AZ 85034 Phone: 602-313-8999 | |
Giovanna Martinez, Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 4125 N 14th St, Phoenix, AZ 85014 Phone: 602-882-5544 | |
Courtney Boyce, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 13201 S Wakial Loop Apt 1094, Phoenix, AZ 85044 Phone: 602-882-2345 |